96 completed, 25 terminated, 14 active not recruiting, 13 recruiting. 164 Phase 2, 25 Phase 1, 5 Phase 3.
Follow Cellcept: new trials by email Literature Review of Cellcept trials Research Report on Cellcept
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial Allogeneic Hematopoietic Stem Cell Transplantation, Axatilimab, Biospecimen Collection - Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Withdrawn | Mayo Clinic | 2026-06-01 | 2026-09-03 | |
| Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies Fludarabine, Intermediate-dose Total Body Irradiation (TBI), Post-transplant Cyclophosphamide (PTCy) - Allogeneic Stem Cell Transplant Recipient | Phase 2 | Recruiting | Hackensack Meridian Health | 209 | 2026-01-06 | 2026-03-23 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Aplastic Anemia | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 1 | 2025-09-25 | 2026-05-22 |
| Belatacept in Heart Transplantation Belatacept, Tacrolimus, Mycophenolate Mofetil/Sodium - Heart Transplant | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 66 | 2025-01-29 | 2026-10-09 |
| A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC) - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Ossium Health, Inc. | 12 | 2024-08-16 | 2026-09-10 |
| Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases Biospecimen Collection, Bone Marrow Aspirate, Cyclophosphamide - Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 54 | 2024-07-23 | 2026-10-26 |
| Advancing Transplantation Outcomes in Children Sirolimus, Belatacept, Mycophenolate Mofetil - Kidney Transplant | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 200 | 2024-05-22 | 2026-10-23 |
| Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency Mycophenolate Mofetil, Tacrolimus, Post-Transplant Cyclophosphamide - GATA2, Immunodeficiency | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 13 | 2023-11-29 | 2026-08-11 |
| De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil - Graft-versus-host Disease | Phase 2 | Active not recruiting | Medical College of Wisconsin | 56 | 2023-08-29 | 2026-03-12 |
| SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease Dapagliflozin 10mg Tab, Standard maintenance therapy - Lupus Nephritis, Chronic Kidney Diseases | Phase 2 | Recruiting | The University of Hong Kong | 150 | 2023-01-04 | 2024-12-16 |
| Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus Mycophenolate Mofetil, Placebo for Mycophenolate Mofetil, Voclosporin - Systemic Lupus Erythematosus | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 12 | 2022-11-30 | 2025-09-09 |
| Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma Anti Thymocyte Globulin, Fludarabine, Cyclophosphamide injection - Neuroblastoma | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 64 | 2022-08-01 | 2022-07-01 |
| Standard Therapy or Individualized Immunosuppression For Lowering Adverse Event Risk Mycophenolate Mofetil - Infection, Transplant;Failure,Kidney | Phase 2 | Withdrawn | University of California, San Francisco | 2022-07-01 | 2022-05-06 | |
| Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Clofarabine - Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2021-10-29 | 2024-01-12 | |
| Two Step Haplo With Radiation Conditioning Fludarabine, Total-Body Irradiation, Donor Lymphocyte Infusion - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | Thomas Jefferson University | 63 | 2021-10-25 | 2025-10-30 |
| Treatment Efficacy of Corticosteroids and Mycophenolate Mofetil in Patients With Immune Related Hepatitis Mycophenolate Mofetil, Solu-Medrol, Ursodeoxycholic acid - Hepatitis, Drug-Induced | Phase 2 | Unknown | Inge Marie Svane | 60 | 2021-04-07 | 2022-12-14 |
| Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis Cyclophosphamide, JAK Inhibitor, Fludarabine - Primary Myelofibrosis, Secondary Myelofibrosis | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 20 | 2021-02-09 | 2026-07-20 |
| Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 60 | 2021-01-25 | 2026-05-29 |
| Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Daratumumab - Recurrent Plasma Cell Myeloma | Phase 2 | Terminated | Srinivas Devarakonda | 1 | 2020-12-22 | 2023-09-28 |
Showing 20 of 164. Sign in to see all of them.
Leukemia, Myeloid, Acute (55) · Leukemia, Lymphocytic, Chronic, B-Cell (44) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (44) · Hodgkin Disease (43) · Lymphoma, Non-Hodgkin (42) · Multiple Myeloma (36) · Myelodysplastic Syndromes (33) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (28) · Lymphoma, Mantle-Cell (25) · Lymphoma, Large B-Cell, Diffuse (24) · Myeloproliferative Disorders (23) · Lymphoma, Follicular (22) · Leukemia, Myelomonocytic, Chronic (20) · Lymphoma, B-Cell, Marginal Zone (20) · Waldenstrom Macroglobulinemia (20)
Fred Hutchinson Cancer Center (49) · M.D. Anderson Cancer Center (12) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (12) · National Institute of Allergy and Infectious Diseases (NIAID) (9) · Stanford University (7) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (6) · Hoffmann-La Roche (3) · University of Nebraska (3) · Amsterdam Molecular Therapeutics (2) · City of Hope Medical Center (2) · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (2) · National Cancer Institute (NCI) (2) · Roswell Park Cancer Institute (2) · University of Miami (2) · Virginia Commonwealth University (2)
United States (147) · Italy (14) · Canada (6) · Germany (5) · Denmark (4) · China (2) · Russia (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Czechia (1) · Hong Kong (1) · New Zealand (1)
Brenda Sandmaier (13) · David Maloney (5) · Dolores Grosso, DNP, CRNP (5) · Neal Flomenberg, MD (5) · Usama Gergis, MD (5) · George Georges (4) · Rachel B. Salit (4) · Marco Mielcarek (3) · Robert Lowsky (3) · Ajay Gopal (2) · Amy E DeZern, MD (2) · Mohamed Sorror (2) · Phuong Vo (2) · Robert Bociek, MD (2)
PMID 32499241, PMID 12176626, PMID 12176628, PMID 15233820, PMID 15692967, PMID 16192477, PMID 16407509, PMID 16790698, PMID 17469162, PMID 17485423, PMID 17717203, PMID 17901414, PMID 18035553, PMID 18424759, PMID 18557726, PMID 18641099, PMID 19066739, PMID 19423725, PMID 19776222, PMID 19892673, PMID 19900571, PMID 20236866, PMID 20528878, PMID 20740615, PMID 21508120, PMID 21508413, PMID 21868572, PMID 22052056, PMID 22438229, PMID 22563089, PMID 22717743, PMID 22946986, PMID 23438305, PMID 23607606, PMID 23903014, PMID 24014509, PMID 24607552, PMID 25085357, PMID 25452309, PMID 26146806, PMID 26183076, PMID 27469583, PMID 28012804, PMID 28038680, PMID 28544580, PMID 29099620, PMID 29296873, PMID 29308669, PMID 30335787, PMID 30454872
P30CA015704 (36), P01CA018029 (11), P01CA078902 (10), P30CA036727 (3), P01CA015396 (2), P01CA049605 (2), P01HL122173 (2), K12HD043494 (1), P01CA044991 (1), P01CA049639 (1), P01DK058335 (1), P30CA006973 (1), P30CA012197 (1), P30CA014520 (1), P30CA072720 (1)